Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TK1 | P04183 | 2/20 | 0.41 |
| ▸ | ALB | P02768 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL9086402 | 0.97 | TK1 (0.39) | LMNATSHRTK1ALBPKM | |
| SCHEMBL6757643 | 0.89 | LMNA (0.36) | LMNATSHRTK1ALBPKM | |
| SCHEMBL6757641 | 0.89 | LMNA (0.36) | LMNATSHRTK1ALBPKM | |
| SCHEMBL10481880 | 0.87 | LMNA (0.37) | LMNATSHRTK1ALBPKM | |
| SCHEMBL10481879 | 0.87 | LMNA (0.37) | LMNATSHRTK1ALBPKM | |
| SCHEMBL9279551 | 0.85 | TK1 (0.44) | LMNATSHRTK1ALBPKM | |
| SCHEMBL10764308 | 0.84 | LMNA (0.35) | LMNATSHRTK1ALBPKM | |
| SCHEMBL18258987 | 0.84 | LMNA (0.32) | LMNATSHRTK1ALBPKM | |
| SCHEMBL1128956 | 0.81 | TK1 (0.48) | LMNATSHRTK1ALBPKM | |
| SCHEMBL1128958 | 0.81 | TK1 (0.48) | LMNATSHRTK1ALBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117616135-A | Subcellular resolution space-time resolved transcriptome | 布罗德研究所股份有限公司 | 2024-02-27 | — | — | CN | claimed |
| CN-112672764-A | Conjugates | 格莱科斯生物医药公司 | 2021-04-16 | — | — | CN | claimed |
| EP-3230455-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTIONS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2017-10-18 | — | — | EP | claimed |
| US-9441227-B2 | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA | CITY OF HOPE (US) | 2016-09-13 | — | — | US | claimed |
| WO-2016092041-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTIONS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-06-16 | — | — | WO | claimed |
| CN-1768075-A | Methods and compositions using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors | AU JESSIE L S (US) | 2006-05-03 | — | — | CN | claimed |
| WO-2004070044-A1 | BIOLOGICALLY-ACTIVE-MOLECULE-ENRICHED PHOTOSYNTHETIC MICRO-ORGANISMS, PREPARATION METHOD THEREOF AND USES OF SAME | BRUNEAU FRANCOIS (FR) | 2004-08-19 | — | — | WO | claimed |
| JP-2002502875-A | — | — | 2002-01-29 | — | — | JP | claimed |
| EP-1061922-A1 | USE OF $i(N)-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2000-12-27 | — | — | EP | claimed |
| WO-1999040916-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1999-08-19 | — | — | WO | claimed |
| US-5744592-A | IMPROVING THE BIOAVAILABILITY AND ABSORPTION OF A DRUG THROUGH THE DIGESTIVE TRACT BY COVALENTLY BONDING THE DRUG AND A 1-O-OR-S-ALKYL-SN-GLYCERO-3-PHOSPHATE | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-04-28 | — | — | US | claimed |
| US-5721241-A | PYRIMIDINE COMPOUND USEFUL TO DISRUPT VIRAL, CANCER, FUNGAL, PARASITE OR BACTERIAL REPLICATION AND DIHYDROURACIL DEHYDROGENASE OR URIDINE PHOSPHORYLASE INHIBITORS | el Kouni, Mahmoud H. (US) | 1998-02-24 | — | — | US | claimed |
| US-5571798-A | TREATMENT OF RETROVIRUS WITH 3-FLUORO-3'-DEOXYTHYMIDINE AND AZIDO DERIVATIVES | MEDIVIR AB (SE) | 1996-11-05 | — | — | US | claimed |
| WO-1994016563-A1 | 1,2-DITHIOLE-3-THIONES FOR THE TREATMENT OF REVERSE TRANSCRIPTASE-DEPENDENT VIRAL INFECTIONS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1994-08-04 | — | — | WO | claimed |
| WO-1993016388-A1 | METHOD OF DETECTING AND MONITORING LEVELS OF 3'-AMINO-3'-DEOXYTHYMIDINE IN BODY FLUIDS AND ANTIBODIES FOR SAME | THE UAB RESEARCH FOUNDATION (US) | 1993-08-19 | — | — | WO | claimed |
| WO-1992017485-A1 | PREPARATION OF 3'-SUBSTITUTED-2',3'-DIDEOXYNUCLEOSIDES AND 2'-DEOXYNUCLEOSIDES FROM ACYCLIC, ACHIRAL PRECURSORS | EMORY UNIVERSITY (US) | 1992-10-15 | — | — | WO | claimed |
| CN-107898790-B | Antiviral JAK inhibitors for the treatment or prevention of retroviral and other viral infections | 埃默里大学 | 2024-06-21 | — | — | CN | disclosed |
| CN-111630183-B | Clear cell renal cell carcinoma biomarker | 新加坡科技研究局 | 2024-06-18 | — | — | CN | disclosed |
| EP-0250234-A1 | Use of specific immunomodulators in treating HIV-induced immunodeficiencies | NEWTHERAPEUTICS LIMITED (GB) | 1987-12-23 | — | — | EP | disclosed |
| EP-0217580-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-04-08 | — | — | EP | disclosed |